AbbVie announced on Thursday that the U.S. Food and Drug Administration has declined to grant approval for trenibotulinumtoxinE, the companys investigational botulinum neurotoxin serotype E intended for use in facial aesthetics. The FDA's decision was driven by questions about the products manufacturing processes rather than any identified problems with safety or effectiveness, the company said.
According to AbbVie, regulators requested further information focused on manufacturing. The agency did not request additional clinical trials and did not cite concerns about the treatment's safety profile or clinical efficacy in its feedback.
TrenibotulinumtoxinE has been evaluated in clinical trials enrolling more than 2,100 patients, including two Phase 3 studies that targeted moderate to severe glabellar lines. The company describes the molecule as a botulinum neurotoxin serotype E that can begin to take effect as soon as eight hours after administration and typically has a duration of two to three weeks.
Roopal Thakkar, AbbVies executive vice president of research and development, highlighted the company's view of the therapy's importance in a statement: "We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics." The quote underscores AbbVies position on the products scientific role, while the firm works to address the FDA's manufacturing questions.
AbbVie said it plans to prepare and submit a response to the FDAs comments in the coming months. The company also noted that regulatory reviews for the same therapy are progressing in other countries, which remain ongoing as the U.S. review is not yet complete.
Contextual notes
- Clinical evidence cited by AbbVie includes two Phase 3 studies and broader trials covering over 2,100 patients.
- The FDAs communication emphasized manufacturing information requests without asking for new clinical research.
- AbbVie intends to respond to the agencys questions within a matter of months and continues parallel regulatory work internationally.